Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Lancet Haematol. 2019 May 17;6(7):e366–e374. doi: 10.1016/S2352-3026(19)30085-7

Figure 1: Overall survival by risk group.

Figure 1:

Figure 1:

Figure 1:

Figure 1:

Figure 1:

Overall survival (OS) by risk group in the ibrutinib phase 3 trials training dataset (A), ibrutinib phase 3 trials internal-validation dataset (B), idelalisib phase 3 trials external-validation dataset (C), venetoclax phase 3 trial external-validation dataset (D), and Mayo Clinic CLL Database external-validation dataset (E).